Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EsPhALL2017 / COG AALL1631: Imatinib with Two Chemotherapy Backbones in Pediatric Ph+ ALL
2024-515499-12-00Phase 3Authorised
- Sponsor
- University of Milano-Bicocca
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised trial of imatinib in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by University of Milano-Bicocca. Primary endpoint: Disease-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on 2024-515499-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515499-12-00.